Krystexxa Anti-Gout Drug Approved by FDA


Krystexxa Anti-Gout Drug Approved by FDA. The U.S Food and Drug Administration has approved a drug to cure gout among adults who cannot tolerate or respond to existing treatments.

The US FDA approved Krystexxa to treat the painful condition which is characterized by swelling, redness, heat, pain and stiffness in the joints. Kyystexxa lowers uric acid levels by metabolizing it into a harmless chemical that is excreted in the urine.

“Since one out of every four patients in the clinical trials experienced a severe allergic reaction when receiving an infusion of Krystexxa, health care providers should dispense a corticosteroid and an antihistamine to their patients beforehand to minimize the risk of such a reaction. Other reactions during the clinical trials included gout flare, nausea, injection site bruising, irritation of the nasal passages, constipation, chest pain and vomiting”, the FDA news release says.

Krystexxa Anti-Gout Drug

Doctors of patients with congestive heart failure should also be cautious in administering Krystexxa because the drug was not studied for this kind of patient. About 3% of the 3 million adults who suffer from gout do not get significant improvement from existing therapies.

Krystexxa is manufactured by Savient Pharmaceutical Inc of East Brunswick NJ.